Background {#Sec1}
==========

*Staphylococcus aureus* is a major pathogen responsible for skin and soft tissue infections (SSTIs) in humans. The number of SSTI episodes with a culture-confirmed pathogen increased from 11 % to 24 % between 1998 and 2009, while the incidence of methicillin-resistant *S. aureus* (MRSA) increased from 5 % in 1998 to 42 % in 2005 before decreasing to 37 % in 2009 \[[@CR1]\]. In the USA, colonization by *S. aureus* is high among SSTI patients, particularly that of USA300 MRSA \[[@CR2]\]. In Taiwan, the prevalence of MRSA in most of the major hospitals ranged from 53 % to 83 % \[[@CR3]\]; MRSA is a major pathogen related to SSTIs \[[@CR4]\].

It is considered that community-acquired (CA)-MRSA strains are more virulent than hospital-acquired (HA)-MRSA because they possess specific virulence factors and they spread more readily than CA-methicillin-sensitive *S. aureus* (CA-MSSA) \[[@CR5], [@CR6]\]. Various extracellular proteins produced by *S. aureus* have been reported to mediate diseases with distinct cutaneous and systemic features. For example, superantigen exotoxin (TSST-1) is associated with staphylococcal toxic shock syndrome, exhibiting desquamative skin rash and multiple organ failure \[[@CR7]\]. Exfoliatin A (ETA) and exfoliatin B (ETB) are associated with staphylococcal scalded-skin syndrome with localized and generalized blister formation \[[@CR8]\]. Panton-Valentine leukocidin (PVL) and γ-hemolysin (Hlg) target immune cells, such as polymorphonuclear cells and macrophages, to cause pus-forming SSTIs \[[@CR9]\]. However, the actual correlations between *S. aureus* virulence factors and the pathogenesis of different SSTI clinical presentations are unclear.

The surgical timing and the choice of empiric antimicrobials when treating *S. aureus*-associated SSTI are still controversial because of different clinical presentations and regional variations in their prevalence \[[@CR10]\]. In this preliminary study, the clinical characteristics of SSTIs, antimicrobial susceptibilities, and the virulence factors of *S. aureus* strains with specific genetic backgrounds were investigated.

Methods {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

This study was performed at the Chiayi Christian Hospital, a 1000-bed teaching hospital in southern Taiwan, between January 2008 and November 2008 and was approved by the research ethics committee of the Chiayi Christian Hospital (097032 and 101051). The medical records of patients diagnosed with SSTI were reviewed, including demographic data, the type of infection, and underlying chronic illnesses (e.g., diabetes mellitus, hypertension, chronic liver disease, coronary artery disease, chronic renal insufficiency, chronic obstructive pulmonary disease, or malignancy). We categorized 307 cases of *S. aureus* SSTIs on the basis of peculiarity and severity of their clinical presentations into six distinct groups as follows: deep-seated infection (necrotizing fasciitis, osteomyelitis, pyomyositis, and septic arthritis), cutaneous infection (cellulitis, bullous impetigo, furuncle, carbuncle, and staphylococcal scalded-skin syndrome), abscess requiring surgical intervention, postpartum mastitis, catheter-related (peritoneal catheter or intravascular catheter) exit-site infection, or SSTI-related bacteremia. We also documented the microbiological data, appropriateness of empiric antibiotics, number of surgical interventions and reconstructions, need for amputation, length of hospital stay, and the in-hospital mortality rate.

Bacterial isolates {#Sec4}
------------------

In total, 307 SSTI-associated *S. aureus* were identified based on their characteristic colony morphology, Gram staining, and the catalase reaction (Staphaurex Plus, Remel, KS, USA). Blood cultures were processed using a VITEK 2 GP system (BioMerieux Vitek, Hazelwood, MO, USA) in the hospital laboratory. *S. aureus* was further confirmed by polymerase chain reaction (PCR) to detect the *clfA*, 16S rRNA, and *nuc* genes, as described previously \[[@CR11]\]. BCRC 10781 and BCRC 15211 were used as the methicillin-susceptible and -resistant reference strains, respectively. The HA-MRSA and CA-MRSA isolates were defined as described previously \[[@CR12]\].

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

Antimicrobial susceptibility was tested using the disc diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute \[[@CR13]\]. We determined the susceptibility to clindamycin, erythromycin, fusidic acid, linezolid, oxacillin, penicillin, rifampicin, teicoplanin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin (BBL, BD, USA). Isolates were considered to be susceptible isolates when their zones of inhibition conformed to the intermediate susceptibility category for a given antibiotic.

PCR identification of staphylococcal cassette chromosome (SCC*mec*) types and genes for virulence factors {#Sec6}
---------------------------------------------------------------------------------------------------------

SCC*mec* types I--IV were identified by multiplex PCR amplification of the SCC*mec* region \[[@CR14], [@CR15]\]. If isolates could not be assigned to types I--IV, they were grouped into SCC*mec* types V or VII based on the PCR detection of *ccrC* (*ccr5*) homologues \[[@CR16]--[@CR18]\]. Genes for virulence factors, namely PVL, Hlg, TSST-1, ETA, and ETB, were identified by simplex and multiplex PCR amplification using primers, as described previously \[[@CR19], [@CR20]\].

Genetic analysis by pulsed field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) {#Sec7}
-------------------------------------------------------------------------------------------------

The genotype of each isolate was identified by *Sma*I-digested PFGE analysis, and the results were visually interpreted as previously described \[[@CR21], [@CR22]\]. The MLST types of 16 CA- and HA-MRSA isolates were identified using the method described by Enright \[[@CR23]\] and by reference to MLST databases (<http://saureus.mlst.net>).

Statistical analysis {#Sec8}
--------------------

Statistical analyses were performed using SPSS 12.0 (SPSS Inc, Chicago, IL, USA). The Student's *t*-test (two-tailed) was used to compare mean values. The clinical and categorical data for SSTI patients infected with MRSA or MSSA were compared by ANOVA (Duncan's test). *P* \< 0.05 was considered statistically significant.

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

Clinical *S. aureus* isolates were collected from 307 SSTI patients, among whom 130 (42.3 %) patients were infected by MSSA and 177 (57.7 %) by MRSA. CA-MRSA and HA-MRSA infections accounted for 68 (38.4 %) and 109 (61.6 %) respectively. Abscess requiring surgical intervention (36.2 %) and cutaneous infection (34.2 %) were the most common clinical features of *S. aureus*-associated SSTI, followed by deep-seated infection (16.9 %), SSTI-related bacteremia (11.4 %), catheter-related exit-site infection (8.1 %), and mastitis (5.2 %). MRSA was more prevalent in all disease groups than MSSA. The most significant predisposing factor was diabetes mellitus (33.6 %), followed by chronic renal diseases (23.5 %) and chronic liver diseases (9.7 %).

Univariate analyses of selected clinical characteristics of SSTI showed significant differences in the clinical presentations of various disease types, excluding the mortality rate. For example, the deep-seated infection group had higher comorbidity and amputation rates than did the abscess group, and the SSTI-related bacteremia group had the highest mean age and duration of hospitalization (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). However, most of the clinical characteristics of MRSA-associated SSTI were similar to those of MSSA-associated SSTIs for each infection type (Table [3](#Tab3){ref-type="table"}), except MRSA-associated deep-seated infections presented with a higher amputation rate than did MSSA-associated ones (20.6 % *vs.* 0, *P* \< 0.05).Table 1Differences in the clinical characteristics of MRSA-associated SSTIs among disease groups according to univariate analysisClinical characteristicsDeep-seated infection (*n* = 34)Cutaneous infection (*n* = 54)Abscess (*n* = 62)Mastitis (*n* = 11)SSTI-related bacteremia (*n* = 23)Catheter-related exit-site infection (*n* = 17)*P*-valueMean age (years)58.4^ab^50.6^bc^39.7^cd^30.7^d^68.3^a^60.8^ab^\<0.001Mean comorbidities2.2^b^ (Range 0--5)1.9^b^ (Range 0--6)0.9^c^ (Range 0--5)0.1^c^ (Range 0--1)3.4^a^ (Range 0--7)3.5^a^ (Range 0--7)\<0.001Mean operative procedure1.2^a^ (Range 0--3)0^c^ (Range 0--1)1.2^a^ (Range 0--6)0.1^bc^ (Range 0--1)0.5^b^ (Range 0--2)0.1^bc^ (Range 0--2)\<0.001Reconstructive surgery (%)4 (11.8)^a^0 (0)^b^1 (1.6)^b^0 (0)^b^0 (0)^b^0 (0)^b^\<0.01Amputation (%)7 (20.6)^a^0 (0)^b^2 (3.2)^b^0 (0)^b^3 (13.4)^ab^0 (0)^b^\<0.001Mean hospitalization days16.9^ab^9.1^b^9.6^b^0.5^c^19.2^a^13.3^ab^\<0.01Mortality (%)0 (0)3 (5.6)0 (0)0 (0)1 (4.3)0 (0)0.248^ab^Values in a row followed by different letters indicate significant difference between groups; *P* \< 0.05Table 2Differences in the clinical characteristics of MSSA-associated SSTI among disease groups according to univariate analysisClinical characteristicsDeep-seated infection (*n* = 18)Cutaneous infection (*n* = 51)Abscess (*n* = 49)Mastitis (*n* = 5)SSTI-related bacteremia (*n* = 12)Catheter-related exit-site infection (*n* = 8)*P*-valueMean age (years)53.7^ab^48.0^ab^39.5^bc^27.0^c^59.9^a^52.9^ab^\<0.05Mean comorbidities2.3^ab^ (Range 0--5)1.5^bc^ (Range 0--6)0.8^cd^ (Range 0--4)0^d^ (Range 0)3.0^a^ (Range 1--7)3.1^a^ (Range 0--7)\<0.001Mean operative procedure1.6^a^ (Range 0--3)0.02^e^ (Range 0--1)1.2^ab^ (Range 1--3)0.2^de^ (Range 0--1)0.6^cd^ (Range 0--3)0.9^bc^ (Range 0--2)\<0.01Reconstructive surgery (%)4 (22.2)^a^0 (0)^b^2 (4.1)^b^0 (0)^b^0 (0)^b^0 (0)^b^\<0.05Amputation (%)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)NAMean hospitalization days13.2^ab^6.9^b^7.7^ab^4.0^b^18.3^a^8.4^ab^\<0.05Mortality (%)0 (0)1 (2.0)1 (2.0)0 (0)0 (0)0 (0)0.974^ab^Values in a row followed by different letters indicate significant difference between groups; *P* \< 0.05Table 3Differences in clinical characteristics between MRSA- and MSSA-associated disease groups according to univariate analysisClinical characteristicsDeep-seated infectionCutaneous infectionAbscessMastitisSSTI-related bacteremiaCatheter-related exit-site infection*P*-valueMRSA (*n* = 34)MSSA (*n* = 18)MRSA (*n* = 54)MSSA (*n* = 51)MRSA (*n* = 62)MSSA (*n* = 49)MRSA (*n* = 11)MSSA (*n* = 5)MRSA (*n* = 23)MSSA (*n* = 12)MRSA (*n* = 17)MSSA (*n* = 8)MRSAMSSAMean age (years)58.453.750.648.039.739.530.727.068.359.960.852.9\<0.001\<0.05Mean comorbidities2.22.31.91.50.90.80.103.43.03.53.1\<0.001\<0.001Mean operative procedure1.21.600.021.21.20.10.20.50.60.10.9\<0.001\<0.01Reconstructive surgery (%)4 (11.8)4 (22.2)0 (0)0 (0)1 (1.6)2 (4.1)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)\<0.01\<0.05Amputation (%)7 (20.6)\*0 (0)0 (0)0 (0)2 (3.2)0 (0)0 (0)0 (0)3 (13.4)0 (0)0 (0)0 (0)\<0.001NAMean hospitalization days16.913.29.16.99.67.70.54.019.218.313.38.4\<0.01\<0.05Mortality (%)0 (0)0 (0)3 (5.6)1 (2.0)0 (0)1 (2.0)0 (0)0 (0)1 (4.3)0 (0)0 (0)0 (0)0.2480.974\*Indicates a significant difference between the MRSA and MSSA groups; *P* \< 0.05

Antimicrobial agents were generally used to treat these SSTIs in both MRSA- and MSSA-infected patients (86.4 % *vs.* 78.5 %). Most patients (93 %) with MSSA infections received an effective empiric antimicrobial agent. However, 78.1 % of the patients with MRSA infections received ineffective empiric antimicrobial therapy, where β-lactam antimicrobials were mostly used. Vancomycin was initially prescribed to treat 6.2 % of the MRSA infections and 7.7 % of the MSSA infections.

SCC*mec* typing and antimicrobial susceptibility testing {#Sec11}
--------------------------------------------------------

The SCC*mec* types of 177 MRSA isolates are shown in Table [4](#Tab4){ref-type="table"}. The *mecA* genes were identified in all (68/68) CA-MRSA strains, 99.1 % (108/109) of HA-MRSA strains, and 2.3 % (3/130) of MSSA strains. The major SCC*mec* types were small-sized SCC*mec* types IV, V, and VII in CA-MRSA strains, and SCC*mec* types III, IV, and V in HA-MRSA strains. SCC*mec* III-carrying isolates were more prevalent in patients with catheter-related exit-site infections (35.3 %) and SSTI-related bacteremia (34.8 %) than patients with mastitis (9.0 %) or abscesses (8.1 %) (*P* \< 0.05). SCC*mec* VII-carrying isolates were more prevalent in patients with abscesses (27.4 %) than in those with catheter-related exit-site infection (0) (*P* \< 0.05) (Table [5](#Tab5){ref-type="table"}).Table 4Differences in prevalence of SCC*mec* types and virulence factors among CA-MRSA, HA-MRSA, and MSSA groupsSCC*mec* types and virulence factorsCA-MRSAHA-MRSAMSSA*P*-value(*n* = 68)(*n* = 109)(*n* = 130)SCC*mec* Type II1 (1.4 %)^c^4 (3.6 %)^b^0 (0)0.393 Type III4 (5.9 %)^c^27 (24.8 %)^a^0 (0)\<0.01 Type IV20 (29.4 %)^a^25 (22.9 %)^a^0 (0)0.339 Type V21 (30.9 %)^a^29 (26.6 %)^a^0 (0)0.541 Type VII15 (22.1 %)^ab^14 (12.8 %)^b^0 (0)0.108 Nontypeable7 (10.3 %)^bc,y^10 (9.2 %)^b,y^130 (100 %)^x^\<0.01  *mecA*68 (100 %)^a^108 (99.1 %)^a^3 (2.3 %)^b^\<0.01Virulence factors PVL51 (75.0 %)^x^36 (33.0 %)^y^32 (24.6 %)^y^\<0.01 Hlg68 (100 %)^x^109 (100 %)^x^120 (92.3 %)^y^\<0.01 TSST-14 (5.8 %)4 (3.7 %)7 (4.6 %)0.725 ETA14 (22.1 %)^y^35 (29.6 %)^x^23 (19.0 %)^y^\<0.01 ETB1 (1.4 %)0 (0)0 (0)0.09^ab^Different letters in the same column indicate significant differences between groups; *P* \< 0.05^xy^Different letters in the same row indicate significant differences between groups; *P* \< 0.05Table 5Differences in the prevalence of SCC*mec* types and virulence factors of MRSA among disease groupsSCC*mec* typeDeep-seated infection (*n* = 34)Cutaneous infection (*n* = 54)Abscess (*n* = 62)Mastitis (*n* = 11)SSTI-related bacteremia (*n* = 23)Catheter-related exit-site infection (*n* = 17)*P*-valueType II2 (5.9 %)2 (3.7 %)1 (1.6 %)0 (0)0 (0)0 (0)0.608Type III9 (26.5 %)^ab^10 (18.5 %)^ab^5 (8.1 %)^b^1 (9.0 %)^b^8 (34.8 %)^a^6 (35.3 %)^a^\<0.05Type IV9 (26.5 %)14 (25.9 %)14 (22.6 %)4 (36.4 %)6 (26.1 %)4 (23.5 %)0.936Type V7 (20.5 %)17 (31.5 %)15 (24.2 %)5 (45.5 %)4 (17.4 %)6 (35.3 %)0.294Type VII4 (11.8 %)^ab^8 (14.8 %)^ab^17 (27.4 %)^a^1 (9.0 %)^ab^3 (13.0 %)^ab^0 (0)^b^\<0.05Non-typeable3 (8.8 %)3 (5.0 %)10 (16.1 %)0 (0)2 (8.7 %)1 (5.9 %)0.101^ab^Values in a row followed by different letters indicate significant differences between groups; *P* \< 0.05

The antibiotic resistance patterns differed significantly among the various SCC*mec* types. The majority of the isolates that contained SCC*mec* IV, V, or VII elements were susceptible to trimethoprim-sulfamethoxazole (SXT) but were resistant to β-lactams, erythromycin, and clindamycin. SCC*mec* type II or III isolates were more resistant to fusidic acid than SCC*mec* type IV, V, or VII isolates (*P* \< 0.05). All *S. aureus* isolates were susceptible to linezolid, teicoplanin, and vancomycin. Most MSSA isolates were susceptible to all antibiotics tested, excluding penicillin. Over 94 % MRSA isolates were resistant to erythromycin and clindamycin. Compared with CA-MRSA isolates, HA-MRSA isolates were more resistant to fusidic acid and SXT (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Antimicrobial susceptibility of CA-MRSA, HA-MRSA, and MSSA. Different letters (a and b) indicate significant differences between groups; *P* \< 0.05

Prevalence of PVL, Hlg, TSST-1, ETA, and ETB genes {#Sec12}
--------------------------------------------------

The PVL gene was identified in 38.8 % *S. aureus* isolates and was significantly more frequent in CA-MRSA strains (75.0 %, 51/68) than in HA-MRSA (33.0 %, 36/109) and MSSA strains (24.6 %, 32/130) (*P* \< 0.01) (Table [4](#Tab4){ref-type="table"}). Irrespective of the methicillin-resistance phenotype, PVL genes were detected most frequently in abscesses, i.e., 66.7 % (74/111), followed by mastitis, cutaneous infections, deep-seated infections, bacteremia, and catheter-related infections. Among all of the SSTI cases, only one ETB gene was identified from a patient with staphylococcal scalded-skin syndrome. Compared with other MSSA disease groups, ETA genes were more common in catheter-related exit-site MSSA infections (37.5 %) (*P* \< 0.05). All the MRSA isolates possessed Hlg genes, which were otherwise only present in 92.3 % of the MSSA isolates (*P* \< 0.01). The TSST-1 gene was seldom identified in any disease type (Table [6](#Tab6){ref-type="table"}).Table 6Differences in virulence factors between MRSA and MSSA among disease groupsVirulence factorDeep-seated infectionCutaneous infectionAbscessMastitisSSTI-related bacteremiaCatheter-related exit-site infectionMRSA (*n* = 34)MSSA (*n* = 18)MRSA (*n* = 54)MSSA (*n* = 51)MRSA (*n* = 62)MSSA (*n* = 49)MRSA (*n* = 11)MSSA (*n* = 5)MRSA (*n* = 23)MSSA (*n* = 12)MRSA (*n* = 17)MSSA (*n* = 8)PVL7 (20.6 %)1 (5.6 %)27 (50.0 %)\*4 (7.8 %)49 (79.0 %)25 (51.0 %)5 (45.5 %)2 (40.0 %)3 (13.0 %)0 (0)1 (5.9 %)0 (0)Hlg34 (100 %)17 (94.4 %)54 (100 %)47 (92.2 %)62 (100 %)46 (93.9 %)11 (100 %)4 (80.0 %)23 (100 %)12 (100 %)17 (100 %)7 (87.5 %)TSST-14 (11.8 %)0 (0)2 (3.7 %)2 (3.9 %)2 (3.2 %)5 (10.2 %)0 (0)0 (0)1 (4.3 %)1 (8.3 %)0 (0)1 (12.5 %)ETA7 (20.6 %)4 (22.2 %)15 (27.8 %)12 (23.5 %)18 (29.6 %)2 (4.1 %)3 (27.3 %)1 (20.0 %)5 (21.7 %)3 (25.0 %)5 (29.4 %)3 (37.5 %)ETB0 (0)0 (0)1 (1.9 %)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)\*Indicates a significant difference between MRSA and MSSA groups; *P* \< 0.05

PFGE analysis {#Sec13}
-------------

PFGE analysis separated 32 MRSA isolates from deep-seated infections into eight pulsotypes, among which pulsotypes A, C, and D accounted for 78.1 % of the isolates. Associations between pulsotypes and SCC*mec* types were determined for pulsotype A with SCC*mec* type II

I (100 %) and pulsotype C with SCC*mec* type IV (88.9 %). Pulsotype D contained diverse SCC*mec* elements (types II, III, V, VII, and nontypeable SCC*mec* elements), but SCC*mec* type V was the major type (40 % of pulsotype D). MLST analysis identified pulsotype A as ST239 and pulsotype C as ST59.

Discussion {#Sec14}
==========

*S. aureus*-associated SSTIs exhibit diverse clinical presentations, mediated by various bacterial toxins and host susceptibility to some extent. Localized cutaneous infections in healthy individuals may resolve spontaneously using topical antimicrobials. However, the majority of abscess-forming lesions usually require surgical intervention. Aggressive antimicrobial treatment of deep-seated infections and SSTI-related bacteremia is crucial for survival. Compared with MSSA infections, MRSA infections may present with different clinical characteristics and outcomes for deep-seated infections, bacteremia, catheter-related infections, and mastitis \[[@CR24]--[@CR26]\]. It has been reported that patients with MRSA bacteremia have a significantly higher mortality rate (15--60 %) and longer hospitalization duration compared with those with MSSA bacteremia \[[@CR27]\]. By contrast, Miller *et al*. reported that most clinical characteristics of MRSA-associated SSTI could not be used as markers to distinguish MSSA-infected patients \[[@CR28]\]. Our results indicate that deep-seated MRSA infections presented with a higher amputation rate than MSSA infections (20.6 % *vs.* 0 %) (Table [3](#Tab3){ref-type="table"}). It should be noted that most patients (78.1 %) with MRSA infections received ineffective empiric antimicrobial therapy. Thus, the correlation between diverse clinical outcomes and inappropriate empiric therapy for severe infections requires further study.

Catheter-related exit-site infection is a peculiar nosocomial infection, which is usually associated with bacterial colonization and biofilm formation in SSTIs, and has been reported as the most common source of *S. aureus* bacteremia, with equal proportions of MSSA and MRSA infection \[[@CR29]\]. Here, patients with catheter-related exit-site MRSA infections were more prevalent and had more concurrent bacteremia (64.7 % *vs.* 0) compared with MSSA infections, suggesting a greater prevalence of MRSA in our hospital.

In general, *S. aureus*, β-hemolytic *streptococcus*, *Escherichia coli*, and *Bacteroides spp.* have been isolated from patients with postpartum mastitis. Among the mastitis-associated MRSA isolates obtained in this investigation, 10/11 (90.9 %) were classified as HA-MRSA strains, but their antimicrobial resistance patterns and PCR results indicated that most isolates possessed the characteristics of CA-MRSA strains.

According to the isolates analyzed by PFGE, the predominant MRSA genotypes were pulsotypes A, C, and D. Pulsotype A isolates related to ST 239 are the major HA-MRSA clones in Taiwan \[[@CR30]\], whereas pulsotype C and D isolates related to ST 59 are the prevalent clones of CA-MRSA in Taiwan \[[@CR3], [@CR31]\]. However, we identified both ST 239 and ST 59 strains from CA and HA-SSTI patients, thereby implying that both strains are circulating concomitantly in community and nosocomial settings.

It was notable that there was a significant association between PVL and MRSA, particularly in cutaneous abscess compared with bacteremia and invasive illnesses. These findings suggest that PVL-positive strains have a higher tendency to develop pus-forming lesions that often require surgical drainages. PVL-positive isolates were significantly more prevalent among the CA-MRSA strains compared with MSSA strains, as described previously \[[@CR32]\], thereby reflecting the consequences of the widespread use of β-lactam antibiotics, leading to the selection of a few restricted PVL-positive MRSA strains. Furthermore, PVL genes were identified in both CA- and HA-MRSA strains that possessed SCC*mec* type III, although SCC*mec* type IV isolates were dominant in both the CA- and HA-MRSA groups (Table [4](#Tab4){ref-type="table"}). Our results suggest that the SCC*mec* types and the presence of PVL genes are not useful molecular markers for distinguishing between CA- and HA-MRSA strains.

TSST-1, ETA, and ETB are reportedly the major virulence factors associated with some peculiar skin and systemic syndromes in clinical settings. The low carriage rate of these genes in *S. aureus* isolates from SSTI patients could explain the low incidence of staphylococcal toxic shock syndrome and staphylococcal scalded-skin syndrome in the present study. Diverse skin and systemic presentations of various disease types of SSTI may be correlated with other exotoxin genes or combinations of virulence factors. The *mecA* gene was not found in an MRSA isolate in this study, which could be related to diverse resistance mechanisms, e.g., the production of β-lactamase or other unidentified factors that may contribute to resistance in MRSA \[[@CR33]\]. Furthermore, three MSSA isolates that possessed the *mecA* gene may have been derived from a *mecA*-positive MRSA strain subpopulation with a heterogeneous resistance phenotype that cannot be detected by traditional susceptibility testing \[[@CR34]\].

The treatment of SSTIs involves topical agents, surgical intervention, or oral or parenteral antimicrobial therapy. Recent reports and the present study demonstrate the high impact of MRSA in SSTIs \[[@CR35]\]. Uncomplicated skin abscesses are curable by surgical drainage alone; antimicrobials are not necessary according to the current guidelines. In areas with a high prevalence of MRSA infections, empiric antimicrobial treatment should consider the possibility of MRSA infection in complicated SSTIs and immunocompromised individuals. CA-MRSA strains with type IV SCC*mec* elements are more susceptible to a variety of non-β-lactam antimicrobials than are HA-MRSA strains \[[@CR36]\]; antimicrobial susceptibility patterns have been used to discriminate CA-MRSA and HA-MRSA strains. However, this approach is now unreliable because CA-MRSA may also acquire resistance to non-β-lactam antibiotics \[[@CR37]\]. Clindamycin has been used as an option for staphylococcal SSTIs due to its good distribution in skin and wound exudates \[[@CR38]\]. However, we found that erythromycin and clindamycin resistance were much more frequent (over 94 %) in both CA- and HA-MRSA isolates than those reported recently from different countries \[[@CR39]\]. The treatment guidelines for MRSA infections should be adjusted according to the currently defined efficacy of non-β-lactam antimicrobials. For complicated SSTIs, the treatment of patients with appropriate initial antimicrobials is associated with a statistically significant impact on the cure rate \[[@CR40]\]. According to the susceptibility tests in the present study, SXT appears to be an appropriate empiric oral antimicrobial for treating CA-MRSA infections, whereas fusidic acid is more suitable for treating both CA- and HA-MRSA infections (Fig. [1](#Fig1){ref-type="fig"}). Vancomycin is warranted only for empiric use when treating deep-seated, life-threatening MRSA infections.

Conclusions {#Sec15}
===========

MRSA is an important emerging pathogen in SSTIs. Most of the clinical characteristics of MRSA-associated SSTIs are similar to those of MSSA-associated SSTIs, except for the higher amputation rate in deep-seated MRSA infections. We found that PVL-positive strains had a higher tendency to cause pus-forming lesions, whereas they were rarely associated with bacteremia and invasive diseases. ETB and TSST-1 genes were identified only rarely in various SSTI disease types. The previously employed criteria and antimicrobial susceptibility patterns for discriminating CA- and HA-MRSA strains are now unreliable because both ST 239 (major clone of HA-MRSA) and ST 59 (major clone of CA-MRSA) strains are circulating concomitantly in community and nosocomial settings in Taiwan. Early surgical drainage of pus-forming lesions and appropriate antimicrobials for invasive infections are mandatory for SSTI treatment. If indicated, the initial empiric antimicrobial treatment should consider MRSA for patients with SSTIs in areas where MRSA is prevalent.

Abbreviations {#Sec16}
=============

CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; CC, clindamycin; CIP, ciprofloxacin; CLSI, Clinical and Laboratory Standards Institute; ETA, exfoliatin A; ETB, exfoliatin B; ERY, erythromycin; FA, fusidic acid; GM, gentamicin; HA-MRSA, hospital-acquired MRSA; Hlg, γ-hemolysin; LZD, linezolid; MLST, multilocus sequence typing; MSSA, methicillin-susceptible *Staphylococcus aureus*; P, penicillin; PFGE, pulsed field gel electrophoresis; PVL, Panton-Valentine leukocidin; RA, rifampicin; SCC*mec*, Staphylococcal Cassette Chromosome *mec*; SSTI, skin and soft tissue infection; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline; TEC, teicoplanin

The authors would like to thank the Chiayi Christian Hospital for financially supporting this research.

Funding {#FPar1}
=======

This work was supported by the Chiayi Christian Hospital under Contract R101-26. The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript

Availability of data and materials {#FPar2}
==================================

We declare that the data supporting the conclusions of this article are fully described within the article.

Authors' contributions {#FPar3}
======================

CHC and CC took initiative in developing the research project and manuscript preparation. YYC and SWC participated in the design, laboratory work, and data analysis. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable

Ethics approval and consent to participate {#FPar6}
==========================================

The study was approved by the research ethics board at the Chiayi Christian hospital (reference number: 097032). Since no patient contact or intervention was carried out, the need for informed consent was waived.
